Peter A. Campochiaro

41.9k citations
382 papers · 28.9k · 13 hit papers · h-index 94

Impact in

  • Ophthalmology top 0.01%
    • Retinal Diseases and Treatments
    • Retinal and Optic Conditions
    • Glaucoma and retinal disorders
    • Ocular Diseases and Behçet’s Syndrome
    • Retinal Imaging and Analysis
    • Retinal and Macular Surgery

Papers in

    • Retinal Diseases and Treatments 261
    • Retinal and Optic Conditions 70
    • Glaucoma and retinal disorders 65
    • Ocular Diseases and Behçet’s Syndrome 23
    • Retinal Development and Disorders 145
    • Angiogenesis and VEGF in Cancer 36

Peter A. Campochiaro

375 papers receiving 28.0k citations

Peter A. Campochiaro's Hit Papers

Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study 2024 · 46 citations
460+8+16Years since publication250500750

Peers

Peter A. Campochiaro
Comparison fields: 5 of 155
  • Ophthalmology 19.2k
  • Radiology, Nuclear Medicine and Imaging 11.4k
  • Molecular Biology 13.4k
  • Neurology 1.1k
  • Cancer Research 1.8k
Replace Anthony P. Adamis with:
Anthony P. Adamis United States
Joan W. Miller United States
Alan C. Bird United Kingdom
Peter Wiedemann Germany
Nagahisa Yoshimura Japan
Abbot F. Clark United States
Gerard A. Lutty United States
Hidenobu Tanihara Japan
Lincoln V. Johnson United States
Jian‐xing Ma United States
Peter A. Campochiaro relative to Anthony P. Adamis United States Anthony P. Adamis's profile →
Citations per field
00.5×1.5×2.2×
Anthony P. Adamis · 1×
Citations per year

Countries citing papers authored by Peter A. Campochiaro

Since Specialization
Citations

This map shows the geographic impact of Peter A. Campochiaro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter A. Campochiaro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter A. Campochiaro more than expected).

Fields of papers citing papers by Peter A. Campochiaro

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter A. Campochiaro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter A. Campochiaro. The network helps show where Peter A. Campochiaro may publish in the future.

Co-authors

The 25 scholars most cited alongside Peter A. Campochiaro, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter A. Campochiaro Line = papers co-authored together Peter A. Campochiaro links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 382 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Ranibizumab for Macular Edema following Central Retinal Vein Occlusion
Hit paper breakdown →
2010926
2
Angiopoietin-2 Is Required for Postnatal Angiogenesis and Lymphatic Patterning, and Only the Latter Role Is Rescued by Angiopoietin-1
Hit paper breakdown →
2002785
3
Ranibizumab for Macular Edema following Branch Retinal Vein Occlusion
Hit paper breakdown →
2010634
4
Sustained Benefits from Ranibizumab for Macular Edema following Central Retinal Vein Occlusion: Twelve-Month Outcomes of a Phase III Study
Hit paper breakdown →
2011575
5
Cell Type–Specific Regulation of Angiogenic Growth Factor Gene Expression and Induction of Angiogenesis in Nonischemic Tissue by a Constitutively Active Form of Hypoxia-Inducible Factor 1
Hit paper breakdown →
2003512
6
Molecular pathogenesis of retinal and choroidal vascular diseases
Hit paper breakdown →
2015408
7
Sustained Benefits from Ranibizumab for Macular Edema Following Branch Retinal Vein Occlusion: 12-Month Outcomes of a Phase III Study
Hit paper breakdown →
2011376
8
Sustained Delivery Fluocinolone Acetonide Vitreous Inserts Provide Benefit for at Least 3 Years in Patients with Diabetic Macular Edema
Hit paper breakdown →
2012376
9
Ranibizumab for Macular Edema Due to Retinal Vein Occlusions
Hit paper breakdown →
2012373
10 2006356
11 2000317
12
Ocular neovascularization
Hit paper breakdown →
2013315
13 1998315
14
Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion
Hit paper breakdown →
2014310
15 2011288
16
Hypoxia inducible factor-1alpha is increased in ischemic retina: temporal and spatial correlation with VEGF expression.
1999283
17 2001274
18 2008266
19 2006265
20 2009264

About Peter A. Campochiaro

Peter A. Campochiaro is a scholar working on Ophthalmology, Molecular Biology, Radiology, Nuclear Medicine and Imaging, Cellular and Molecular Neuroscience and Neurology, having authored 382 papers that have together received 28.9k indexed citations. Recurring topics across this work include Retinal Diseases and Treatments (261 papers), Retinal Development and Disorders (145 papers), Retinal and Optic Conditions (70 papers), Glaucoma and retinal disorders (65 papers), Retinal Imaging and Analysis (60 papers), Retinal and Macular Surgery (58 papers), Angiogenesis and VEGF in Cancer (36 papers) and Ocular Diseases and Behçet’s Syndrome (23 papers). The work is most often cited by research in Ophthalmology (19.2k citations), Radiology, Nuclear Medicine and Imaging (11.4k citations), Molecular Biology (13.4k citations), Neurology (1.1k citations) and Cancer Research (1.8k citations). Peter A. Campochiaro has collaborated with scholars based in United States, United Kingdom and Japan. Frequent co-authors include Sean F. Hackett, Roman G. Rubio, Donald J. Zack, Sean F. Hackett, Namrata Saroj, Bert M. Glaser, David M. Brown, Stanley A. Vinores, Sarah Gray and Wendy Yee Murahashi. Their work appears in journals such as Investigative Ophthalmology & Visual Science, Ophthalmology, Journal of Cellular Physiology, American Journal of Ophthalmology and Experimental Eye Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact